Repligen said it will acquire BioLife Solutions in a deal valuing the cell-processing company at about $1.5 billion, with BioLife stockholders set to receive $11.25 in cash and 0.1442 Repligen shares for each share, or $31.00 a share. The offer implies a 24% premium to BioLife’s 90-day volume-weighted average price through July 21, 2026.
The consideration is split 64% stock and 36% cash. Repligen said the cash portion will come from cash on hand, and it expects to end with more than $300 million of pro forma cash and cash equivalents after the transaction.
The companies said the deal should add at least $20 million of synergies in year one and at least $30 million in year two, driven by public-company cost savings, G&A efficiencies, and manufacturing and supply-chain optimization. Repligen also said the acquisition should lift top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two.
BioLife reported preliminary second-quarter revenue of $28.5 million, up 21% from $23.4 million a year earlier. Repligen said its preliminary second-quarter revenue rose about 12% as reported and 13% on an organic basis versus the same quarter in 2025, and it expects strong year-over-year margin expansion.
BioLife’s biopreservation media platform, led by CryoStor, is used in 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials, according to the companies.
The transaction is expected to close in the fourth quarter of 2026. The market has reacted to these announcements by moving the company's shares 2.12% to a price of $139.89. For the full picture, make sure to review REPLIGEN CORP's 8-K report.
